Congratulations to Dr. Andrea Hawkins-Daarud on her new paper in Journal of the Royal Society Interface


Written on May 25th, 2016

In Silico Analysis Suggests Differential Response to Bevacizumab and Radiation Combination Therapy in Newly Diagnosed Glioblastoma

 

404 Not Found

404 Not Found


nginx
Andrea Hawkins-Daarud, Russell Rockne, David Corwin, Alexander R. A. Anderson and Kristin R. Swanson

 
Recently, two phase III studies of bevacizumab, an anti-angiogenic, for newly diagnosed glioblastoma (GBM) patients were released. While they were unable to statistically significantly demonstrate that bevacizumab in combination with other therapies increases the overall survival of GBM patients, there remains a question of potential benefits for subpopulations of patients. We use a mathematical model of GBM growth to investigate differential benefits of combining surgical resection, radiation and bevacizumab across observed tumour growth kinetics. The differential hypoxic burden after gross total resection (GTR) was assessed along with the change in radiation cell kill from bevacizumab-induced tissue re-normalization when starting therapy for tumours at different diagnostic sizes. Depending on the tumour size at the time of treatment, our model predicted that GTR would remove a variable portion of the hypoxic burden ranging from 11% to 99.99%. Further, our model predicted that the combination of bevacizumab with radiation resulted in an additional cell kill ranging from 2.6×107 to 1.1×1010 cells. By considering the outcomes given individual tumour kinetics, our results indicate that the subpopulation of patients who would receive the greatest benefit from bevacizumab and radiation combination therapy are those with large, aggressive tumours and who are not eligible for GTR.
 

http://rsif.royalsocietypublishing.org/content/12/109/20150388


© 2017 Mathematical NeuroOncology (MNO). Website designed by Mihafa.com.

.